EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

CURRENT OPTIONS FOR THERAPEUTIC MANAGEMENT OF ESOPHAGEAL CANCER IN TERTIARY CARE HOSPITAL

Beulah Mariam Jacob*, Bobas Jose, Axa Mariam Babu, Amratha Johnson, Rilly Anil Mathew, and Janaki Torvi

ABSTRACT

Background and aim: The multistep process of carcinogenesis includes the stages of initiation, promotion, conversion, and progression. Clinical trials are being conducted on combined modality therapies, which include surgery alone, chemotherapy, immunotherapy, and radiation therapy. The aim of the study is to analyze and evaluate the current options for therapeutic management of oesophageal cancer dose, frequency and route of administration using WHO and NIH as reference therapy. Materials & Methods: It was a prospective observational study on Oesophageal cancer patients that was carried out in collaboration with the Department of Medical Oncology at KIMS, Hubli, Karnataka. The study was conducted for a period of 6 months from March 2022 to August 2022. A sample size of 100 people was included in the study. The study inclusion criteria selected people with esophageal cancer, people of all age, people of either sex and people with oesophageal cancer with comorbid conditions. Result: The study’s finding presented that the majority of the treatments given for esophageal patients were chemotherapy. In surgery procedures, feeding jejunostomy was mostly done. Cisplatin is given mostly as monotherapy and carboplatin + paclitaxel was given mostly as combination therapy. Conclusion: Chemotherapy emerges as the most effective treatment for esophageal cancer patients in this study. Although treatment outcomes have improved and death rates have decreased in recent years, there is still room for enhancement in the treatment plan. Despite advances in multimodal treatments, the overall prognosis for esophageal cancer remains challenging.

Keywords: Oesophageal cancer, squamous cell carcinoma, adenocarcinoma, cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, paclitaxel.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • EJPMR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2024 issue has been successfully launched on 1 FEBRUARY 2024.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia